BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 15493565)

  • 1. Efficacy of recombinant human follicle-stimulating hormone in improving oocyte quality in assisted reproductive techniques.
    Cheon KW; Byun HK; Yang KM; Song IO; Choi KH; Yoo KJ
    J Reprod Med; 2004 Sep; 49(9):733-8. PubMed ID: 15493565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
    Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
    Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial.
    Andersen AN; Devroey P; Arce JC
    Hum Reprod; 2006 Dec; 21(12):3217-27. PubMed ID: 16873892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles.
    Barrenetxea G; Agirregoikoa JA; Jiménez MR; de Larruzea AL; Ganzabal T; Carbonero K
    Fertil Steril; 2008 Mar; 89(3):546-53. PubMed ID: 17531989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI.
    Bjercke S; Tanbo T; Abyholm T; Omland A; Opøien HK; Fedorcsak P
    Acta Obstet Gynecol Scand; 2010 Aug; 89(8):1053-60. PubMed ID: 20602599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of recombinant versus human derived follicle stimulating hormone on the oocyte and embryo quality in IVF-ICSI cycles: Randomised, controlled, multi-centre trial.
    Abate A; Nazzaro A; Salerno A; Marzano F; Pavone Cossut MR; Perino M
    Gynecol Endocrinol; 2009 Aug; 25(8):479-84. PubMed ID: 19572228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of in vitro fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial.
    Ye H; Huang G; Pei L; Zeng P; Luo X
    Gynecol Endocrinol; 2012 Jul; 28(7):540-4. PubMed ID: 22390186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two different fixed doses of follitropin-beta in controlled ovarian hyperstimulation: A prospective randomized, double blind clinical trial.
    Pruksananonda K; Suwajanakorn S; Sereepapong W; Virutamasen P
    J Med Assoc Thai; 2004 Oct; 87(10):1151-5. PubMed ID: 15560689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant FSH vs. urinary FSH for ovarian stimulation in in vitro fertilization.
    Meden-Vrtovec H; Mocnik-Roznik S; Tomazevic T; Virant-Klun I
    J Reprod Med; 2003 Oct; 48(10):799-803. PubMed ID: 14619648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy outcome following in vitro fertilization-embryo transfer (IVF-ET) in women aged < 37, undergoing ovulation induction with human FSH compared with recombinant FSH: a randomised controlled study.
    Gholami H; Vicari E; Molis M; La Vignera S; Papaleo E; Cappiello F
    Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):97-102. PubMed ID: 20329567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
    De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
    Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cumulative live birth rate of recombinant follicle-stimulating hormone alfa verse urinary human follicle-stimulating hormone for ovarian stimulation in assisted reproductive technology cycles.
    Yang C; Dong N; Li F; Ji Y; Pan Y; She H
    J Ovarian Res; 2022 Jun; 15(1):74. PubMed ID: 35729654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
    Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
    J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
    Majumder K; Gelbaya TA; Laing I; Nardo LG
    Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.
    Daya S; Gunby J
    Cochrane Database Syst Rev; 2000; (4):CD002810. PubMed ID: 11034767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle.
    Pacchiarotti A; Aragona C; Gaglione R; Selman H
    J Assist Reprod Genet; 2007 Sep; 24(9):400-5. PubMed ID: 17653846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.